对他类药物不耐受性和佩多酸的实际应用进行了全面的审查
Siva Naga S Yarrarapu1, Amandeep Goyal2, Vikramaditya Samala Venkata3
1Department of Internal Medicine, Rutgers/Monmouth Medical Center, Long Branch, NJ, USA.
Journal of cardiology
|March 23, 2024
概括
班佩多酸 (BA) 有效降低了对他类药物不耐受患者的LDL胆固醇,为心血管提供了好处. 它是一种有价值的辅助疗法,用于管理超脂血症,当他类药物不能耐受时.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 达他林不耐受性影响8-10%的患者,主要是由于肌肉不适.
- 班佩多酸 (BA) 是一种ATP酸酶抑制剂,可降低肝脏胆固醇合成.
- BA上调调节LDL受体,增强循环中的LDL胆固醇的清除.
研究的目的:
- 评估贝佩多酸在患有他类药物不耐受症的患者中的疗效和安全性.
- 评估BA在管理高脂血症和心血管风险方面的作用.
- 审查临床试验数据和FDA批准的BA.
主要方法:
- 对Bempedoic酸的多个随机临床试验的分析.
- 审查来自CLEAR OUTCOME试验的数据.
- 检查FDA批准的指示和报告的不良事件.
主要成果:
- 在对他类药物不耐受的患者中,BA证明了17-28%的LDL降低.
- "清晰的结果"试验证实了显著的心血管益处.
- 在糖尿病患者中,BA显示HbA1c的适度降低0.12%.
结论:
- 班佩多酸有效降低了对他类药物不耐受的人的LDL胆固醇.
- BA已被批准用于特定的患者群体,并且可以与最大耐受度的他类药物剂量一起使用.
- 需要在不同人群中进行进一步的研究,并且在不同水平的LDL中进行进一步的研究.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
659
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
659
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Factors Influencing Drug Absorption: Presystemic Elimination
215
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
215
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
206
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
206
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522


